CAR-T Summit
July 25, 2022
November 12-13, 2015 – Cambridge, MA
First-in-class CAR-T therapy for HCC via targeting an AFP-MHCI complex
Menu
4th Annual Cell Line Development & Engineering Asia Conference
July 25, 2022
May 19-22, 2015 – Shanghai, China
Assessment of antibody Fc mediated effector functions via multiple assay platforms
Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80
June 6, 2022
Emeryville, California, June 6, 2022 — Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer
May 31, 2022
EMERYVILLE, Calif., and LOS ANGELES, May 31, 2022 — Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid
A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematological malignancies
May 20, 2022
Blood. April 15 2022: Martin G Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M Dacek, Hanzhi Luo, Thomas J Gardner, Christopher M Bourne, Leila Peraro, Zita E H Aretz, Tanya Korontsvit, Michael Lau, Michael Gregory Kharas, Cheng Liu, David A Scheinberg
Bispecific T-cell engaging antibodies against MUC16 demonstrate efficacy against ovarian cancer in monotherapy and in combination with PD-1 and VEGF inhibition
May 2, 2022
Frontiers in Immunology. 14 April 2021: Oladapo O. Yeku, Thapi Dharma Rao, Ian Laster, Artem Kononenko, Terence J. Purdon, Pei Wang, Ziyou Cui, Hong Liu, Renier J. Brentjens and David Spriggs
Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody
May 2, 2022
Journal OncoImmunology. 15 April 2019: Tao Dao, Sung Soo Mun, Andrew C. Scott, Casey A. Jarvis, Tatyana Korontsvit, Zhiyuan Yang, Lianxing Liu, Martin G. Klatt, Manuel Guerreiro, Annamalai Selvakumar, Elliott J. Brea, Claire Oh, Cheng Liu & David A. Scheinberg
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
May 2, 2022
Science Translational Medicine. 27 March 2019: E L Smith, K Harrington, M Staehr, R Masakayan, J Jones, T J Long, K Y Ng, M Ghoddusi, T J Purdon, X Wang, T Do, M T Pham, J M Brown, C F De Larrea, E Olson, E Peguero, P Wang, H Liu, Y Xu, S C Garrett-Thomson, S C Almo, H-G Wendel, I Riviere, C Liu, B Sather & R J Brentjens
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
May 2, 2022
Cell Discovery. 20 November 2018: Yiyang Xu, Zhiyuan Yang, Lucas H. Horan, Pengbo Zhang, Lianxing Liu, Bryan Zimdahl, Shon Green, Jingwei Lu, Javier F. Morales, David M. Barrett, Stephan A. Grupp, Vivien W. Chan, Hong Liu & Cheng Liu
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
May 2, 2022
Nature Biotechnology. 1 October 2018: Sarwish Rafiq, Oladapo O Yeku, Hollie J Jackson, Terence J Purdon, Dayenne G van Leeuwen, Dylan J Drakes, Mei Song, Matthew M Miele, Zhuoning Li, Pei Wang, Su Yan, Jingyi Xiang, Xiaojing Ma, Venkatraman E Seshan, Ronald C Hendrickson, Cheng Liu & Renier J Brentjens
